Table 5.
Difference in proinflammatory cytokines between patients with and without clinical treatment progress.
| Difference in proinflammatory cytokines | NP group (N = 12) |
ET group (N = 10) |
P valuea | ||
|---|---|---|---|---|---|
| Median | Q1–Q3 | Median | Q1–Q3 | ||
| IL-1α | −11.97 | −39.08–45.53 | 142.70 | 37.5–188.77 | 0.02 |
| IL-1β | −28.38 | −118.3–2.99 | −0.13 | −14.53–0.86 | 0.04 |
| IL-6 | −0.72 | −7.19–0.05 | 3.33 | 2.76–10.18 | 0.0014 |
| IL-8 | −87.31 | −133.23–−38.42 | 7.84 | −51.79–64.65 | 0.02 |
| TNF-α | 0.11 | 0.00–1.02 | 0.41 | −0.11–1.47 | 0.97 |
| TNF-β | −0.01 | −0.04–0.08 | 0.01 | −0.02–0.16 | 0.45 |
aMann-Whitney U test.
NP group: nonprogress treatment group.
ET group: effective treatment group.